HFS
VTGN icon

Hantz Financial Services’s VistaGen Therapeutics VTGN Stock Holding History

Hantz Financial Services’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-867
Closed -$4K – 1162
2022
Q3 		$4K Hold
867
– – ﹤0.01% 895
2022
Q2 		$23K Hold
867
– – ﹤0.01% 655
2022
Q1 		$32K Buy
+867
New +$37.8K ﹤0.01% 650

Other funds holding VTGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Hantz Financial Services's VTGN Position: Q4 2022 in Review

Hantz Financial Services sold out of VistaGen Therapeutics (VTGN) in Q4 2022, closing a stake of 867 shares — an estimated $4K sold.

Hantz Financial Services first reported a position in VTGN in Q1 2022 and held it in 3 quarters. The position peaked at $32K in Q1 2022. 85 funds tracked by Wall St. Rank hold VTGN as of Q4 2022.

  • Hantz Financial Services reported no remaining VistaGen Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Hantz Financial Services sold 867 VistaGen Therapeutics shares in Q4 2022, an estimated $4K.
  • Hantz Financial Services first reported a position in VistaGen Therapeutics in Q1 2022 and held it in 3 quarters.
  • Hantz Financial Services's VistaGen Therapeutics position peaked at $32K in Q1 2022.
  • 85 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q4 2022.

Based on Hantz Financial Services's 13F filing for Q4 2022, filed 15 Feb 2023.